Hemolytic Anemia
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Hemolytic Anemia

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Hemolytic Anemia Local Doctors?
Elite in Hemolytic Anemia
Elite in Hemolytic Anemia

Jefferson Hematology - Honickman Center

1101 Chestnut Street, Floor 8, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Sophie Lanzkron is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Lanzkron is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Lanzkron is board certified in Hematology. Dr. Lanzkron is currently accepting new patients.

Elite in Hemolytic Anemia
Pathology | Hematology | Oncology
Elite in Hemolytic Anemia
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is board certified in American Board Of Internal Medicine.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hemolytic Anemia
Elite in Hemolytic Anemia

Duke Adult Comprehensive Sickle Cell Center - Clinic 2N

40 Duke Medicine Cir, 
Durham, NC 
Experience:
53+ years
Languages Spoken:
English, French, Russian
Offers Telehealth

Marilyn Telen is a Hematologist practicing medicine in Durham, North Carolina. She has been practicing medicine for over 53 years. Dr. Telen is rated as an Elite provider by MediFind in the treatment of Hemolytic Anemia. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Telen is board certified in American Board Of Internal Med, Hematology/Oncology and American Board Of Internal Med, Internal Medicine.

What are the latest Hemolytic Anemia Clinical Trials?
The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening disease that occurs at any age, with incidence rate of 0.75 to 2.0 cases per million population per year. aHUS is a thrombotic microangiopathy (TMA) commonly caused by dysregulation of the complement system, affecting several organs, especially the kidneys. aHUS can be familial or sporadic, and approximately 50%...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

Summary: This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells ...